Aktivne farmacevtske sestavine
| Progestagen in estrogen | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| progesteron | CP/EP/USP/JP | CEP/EU-GMP/FDA | 57-83-0 |
| Pregnenolon | V hiši |
košer | 145-13-1 |
| Medroksiprogesteron Acetat | CP/EP/USP/JP | DMF/GMP | 71-58-9 |
| Megestrol acetat | CP/EP/USP | DMF v postopku | 595-33-5 |
| Mifepriston | CP/IP | DMF/GMP | 84371-65-3 |
| Ciproteron acetat | CP/EP/IP/KP | CEP/TGA/EU-GMP | 427-51-0 |
| levonorgestrel | CP/EP/USP/IP | CEP/GMP | 797-63-7 |
| Noretisteron |
CP/EP/USP/JP |
DMF v postopku |
68-22-4 |
| Noretisteronacetat |
EP/USP |
DMF v postopku |
51-98-9 |
| Noretisteron enantat |
V hiši |
V okviru raziskav in razvoja |
3836-23-5 |
| Drospirenon | EP/USP | DMF | 67392-87-4 |
| Gestoden | CP/EP | DMF/GMP | 60282-87-3 |
| Estradiol | CP/EP/USP/KP | DMF/GMP/WC | 35380-71-3 |
| Estriol | CP/EP/USP | V okviru raziskav in razvoja | 50-27- 1 |
| Etinilestradiol | CP/EP/USP | GMP | 57-63-6 |
| Estradiol Valerat | CP/EP/USP/KP | DMF | 979-32-8 |
| Estradiol cipionat |
USP | DMF v postopku |
313-06-4 |
| Promestriene |
V hiši |
V okviru raziskav in razvoja |
39219-28-8 |
| Tibolon | CP/EP | DMF/GMP | 5630-53-5 |
| Dienogest | EP | CEP/GMP | 65928-58-7 |
| Fulvestrant | EP/USP | V okviru raziskav in razvoja | 129453-61-8 |
| Eksemestan | CP/EP/USP | V okviru raziskav in razvoja | 107868-30-4 |
| Androgen | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| Finasterid | CP/EP/USP | CEP/FDA/PMDA/GMP | 98319-26-7 |
| Dutasterid | EP/USP | CEP/FDA | 164656-23-9 |
| Abirateronacetat | CP/USP | DMF/GMP/WC | 154229-18-2 |
| darolutamid |
V hiši |
V okviru raziskav in razvoja |
1297538-32-9 |
| Testosteron | CP/EP/USP | CEP/FDA/WC | 58-22-0 |
| Testosteron undekanoat | CP | DMF/WC | 5949-44-0 |
| Testosteron Cypionate | USP | DMF | 58-20-8 |
| Testosteron Enanthate |
USP/JP | V okviru raziskav in razvoja |
315-37-7 |
| Testosteron propionat |
CP/EP/USP/JP |
V okviru raziskav in razvoja |
57-85-2 |
| DHEA | FP/V hiši | DMF/WC/Košer | 53-43-0 |
| Klaskoteron | V hiši | DMF v postopku | 19608-29-8 |
| Kortikalni hormon | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| Budezonid | CP/EP/USP/JP | CEP/FDA/GMP | 51333-22-3 |
| Desonid | CP/USP | DMF/GMP | 638-94-8 |
| Eplerenon | EP | CEP v postopku | 107724-20-9 |
| Metilprednizolon | CP/EP/USP/JP | DMF/GMP | 83-43-2 |
| Metilprednizolon Hemisukcinat | CP/EP/USP | DMF/GMP | 2921-57-5 |
| Flutikazon propionat | CP/EP/USP | DMF | 80474- 14-2 |
| Flutikazon furoat | CP/EP | DMF v postopku | 397864-44-7 |
| Mometazon furoat |
CP/EP/USP |
DMF v postopku |
brezvodni (83919-23-7) Monohidrat (141646-00-6) |
| Deflazakort |
V hiši |
V okviru raziskav in razvoja |
14484-47-0 |
| drugi | |||
| Ime izdelka | Specifikacija | Odobreno | št. CAS |
| okskarbazepin | CP/EP/USP/IP | CEP/FDA/GMP | 28721-07-5 |
| Eslikarbazepinacetat | CP/USP | DMF | 236395- 14-5 |
| ganciklovir | CP/EP/USP | DMF/GMP | 82410-32-0 |
| Valganciklovir hidroklorid | USP/EP | CEP v postopku | 175865-59-5 |
| Oseltamivir fosfat | CP/EP/USP | DMF | 204255- 11-8 |
| Baloxavir Marboxil | V hiši | V okviru raziskav in razvoja | 1985606-14-1 |
| Revefenacin | V hiši | DMF | 864750-70-9 |
| Mirabegron | CP/EP | DMF | 223673-61-8 |
| Vibegron |
V hiši |
V okviru raziskav in razvoja |
1190389-15-1 |
| Escitalopram oksalat | CP/EP/USP | DMF v postopku | 219861-08-2 |
| Citalopram hidrobromid |
CP/EP/USP |
DMF v postopku |
59729-32-7 |
| kariprazin hidroklorid | V hiši | DMF | 1083076-69-0 |
| Lasmiditan sukcinat | V hiši | DMF | 439239-92-6 |
| lulikonazol | V hiši | DMF | 187164-19-8 |
| Nintedanib Esylate |
V hiši |
FDA/DMF/WC |
656247-18-6 |
| Apalutami | V hiši | DMF | 956104-40-8 |
| Tadalafil | CP/EP/USP | V okviru raziskav in razvoja | 171596-29-5 |
| Relugoliks | V hiši | DMF v postopku | 737789-87-6 |
| Ruksolitinib fosfat |
V hiši |
DMF v postopku |
1092939-17-7 |
| Abemaciklib |
V hiši |
V okviru raziskav in razvoja |
1231929-97-7 |
| floroglucinol | CP/EP | DMF | 108-73-6 |
| 1,3,5-trimetoksibenzen |
CP/notranji |
GMP |
621-23-8 |
| Ursodeoksiholna kislina | EP/USP/JP | V okviru raziskav in razvoja | 128-13-2 |
| Tauroursodeoksiholna kislina |
V hiši |
V okviru raziskav in razvoja |
14605-22-2 |
| holesterol |
CP/EP/USP/JP |
V okviru raziskav in razvoja |
57-88-5 |
| Omega-3-kislinski etil etri 90 |
EP/USP |
DMF v postopku |
—— |
| Srednjeverižni trigliceridi |
CP/USP/EP |
DMF |
—— |
| Benzalkonijev klorid |
USP/EP/JP |
CEP v postopku |
8001-54-5 |
| Oljčno olje (za injiciranje) |
CP/USP/EP/JP |
DMF v postopku |
8001-25-0 |
| Jajčni fosfolipidi (za injiciranje) |
CP/USP/EP |
DMF |
93685-90-6 |
| Prigrizek |
V hiši |
DMF v postopku |
203787-91-1 |
Za metilprednizolon hemisukcinat imamo specifikacije EP, USP in CP. DMF in WC na voljo.
Za Cyproterone Acetate (CPA) imamo na voljo specifikacije CP in EP, CEP/TGA/EU-GMP.
Levonorgestrel ima specifikacije CP/EP/USP. Na voljo so DMF, GMP in CEP.
Mifepriston ima specifikacije CP in IP. DMF in GMP sta odobrena.
Tibolon je skladen s specifikacijo EP. DMF je odobren.
Estradiol hemihidrat ima specifikacijo USP in EP. DMF na voljo.